Cardiometabolic risk factors efficacy of semaglutide in the STEP program.

Amaro A, Skolnik NS, Sugimoto D. Cardiometabolic risk factors efficacy of semaglutide in the STEP program. Postgrad Med. 2022 Jan; 134(sup1):18-27.

View in: PubMed

subject areas

Cardiovascular Diseases
Diabetes Mellitus, Type 2
Glucagon-Like Peptides
Humans
Hypoglycemic Agents
Lipids
Obesity
Overweight
Weight Loss

authors with profiles

Neil Skolnik

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement